TSRI-invented compound ozanimod shows positive results in late-stage clinical trial for relapsing multiple sclerosis
Credit: The Scripps Research Institute February 21, 2017 – Results from a new Phase 3 study conducted by the Celgene Corporation demonstrate that ozanimod, a...

